Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
280 participants
INTERVENTIONAL
2021-07-19
2024-02-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vehicle
Vehicle, topical liniment, administered once at baseline
Vehicle
topical liniment without investigational product
ET-01, Dose 1
Dose 1 of botulinum toxin, Type A, topical liniment, administered once at baseline. 250µm microneedle length
botulinum toxin, Type A
ET-01 topical liniment
ET-01, Dose 2
Dose 2 of botulinum toxin, Type A, topical liniment, administered once at baseline. 250µm microneedle length
botulinum toxin, Type A
ET-01 topical liniment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vehicle
topical liniment without investigational product
botulinum toxin, Type A
ET-01 topical liniment
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 25 - 65 years of age
* willing to have facial pictures/videos taken per protocol
* mild or less Crow's Feet wrinkles (IGA 0-2) "at rest"
* moderate to severe Crow's Feet (IGA 3-4) "on contraction"
* ability to correctly grade a series of Crow's Feet pictures
* moderate to severe Crow's Feet (SSA 3-4) "on contraction"
* have adequate vision without the use of eyeglasses to assess facial wrinkles in a mirror (contact lenses are OK)
* willingness to refrain from the use of facial fillers, retinoids, botulinum toxins, laser treatments, or any product affecting skin remodeling or that might cause an active dermal response during the course of the study
* female subjects of childbearing potential must have a negative urine pregnancy test and be non-lactating at the Baseline visit
* female subjects of childbearing potential must utilize one of the following methods of birth control throughout the study: intra-uterine device (IUD), diaphragm, a condom, a spermicidal gel or foam, oral contraceptives (provided subject has been utilizing this method for at least 3 months prior to Baseline and has not changed the brand within this period), or patch, injectable, implantable, or vaginal ring contraceptives. Subjects may also participate if they are surgically sterilized (tubal sterilization or hysterectomy) or are in menopause.
* subjects should be in good general health as determined by the Investigator and free of any disease that may interfere with study evaluations or the Investigational Product.
Exclusion Criteria
* history of vaccination with botulinum toxin
* history of non-response to any prior botulinum toxin treatments
* any botulinum toxin treatment anywhere in the prior 6 months
* history of participation in ET-01-LCL-210 in previous Cohorts 1 or 2 at any time in the past
* history of periocular surgery, brow lift or related procedures
* soft tissue augmentation or any procedures affecting the lateral canthal region in the prior 12 months
* dermabrasion or laser treatment in the periocular region in the last 6 months
* topical prescription-strength retinoids in the prior 3 months to the treatment area
* application of any topical prescription medication to the treatment area within 14 days prior to treatment
* subjects on clinically significant, concomitant drug therapy (See Section 5.3 below).).
* present or history of neuromuscular disease, eyelid ptosis, muscle weakness or paralysis
* present or history of "dry eye"
* hemophilia, hemorrhagic disorder, hemostatic dysfunction or other blood clotting disorders
* use of systemic aminoglycosides in the week prior to treatment application
* participation in another investigational drug trial or receiving any investigational treatment(s) within 30 days of Baseline
* alcohol or drug abuse within the past 3 years
* psychiatric disease interfering with the subject's ability to give informed consent
* refusal or inability to comply with the requirements of the protocol for any reason
25 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eirion Therapeutics Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eirion Research Site
Scottsdale, Arizona, United States
Eirion Research Site
San Diego, California, United States
Eirion Research Site
Aventura, Florida, United States
Eirion Research Site
Boca Raton, Florida, United States
Eirion Research Site
Miami, Florida, United States
Eirion Research Site
West Palm Beach, Florida, United States
Eirion Research Site
Chicago, Illinois, United States
Eirion Research Site
Louisville, Kentucky, United States
Eirion Research Site
New Orleans, Louisiana, United States
Eirion Research Site
Glenn Dale, Maryland, United States
Eirion Research Site
Clinton Township, Michigan, United States
Eirion Research Site
New Brighton, Minnesota, United States
Eirion Research Site
New York, New York, United States
Eirion Research Site
Exton, Pennsylvania, United States
Eirion Research Site
Newtown Square, Pennsylvania, United States
Eirion Research Site
Greenville, South Carolina, United States
Eirion Research Site
Houston, Texas, United States
Eirion Research Site
Plano, Texas, United States
Eirion Research Site
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ET-01-LCL-210
Identifier Type: -
Identifier Source: org_study_id